Business
Hemostemix Announces the Appointment of Dr. Johannes Grillari to its Scientific Advisory Board
Calgary, Alberta--(Newsfile Corp. - September 15, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: ...
About this update from Hemostemix Inc
[{"type":"text","content":"Hemostemix Announces the Appointment of Dr. Johannes Grillari to its Scientific Advisory BoardCalgary, Alberta--(Newsfile Corp. - September 15, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (\"Hemostemix\" or the \"Company\") is pleased to announce the appointment of Dr. Johannes Grillari to its Scientific Advisory Board.Since 2019, Dr. Johannes Grillari is the director of the Ludwig Boltzmann Institute for Traumatology (LBI Trauma) - the Research Center in cooperation with AUVA, Vienna, Austria which is the central research unit of seven trauma centers and four rehabilitation centers with a strong focus on tissue regeneration.In his research, Dr. Grillari focuses on improving our understanding of the molecular and physiological changes that occur during cellular aging, their impact on organismal aging and tissue regeneration, specifically in skin and bone. In addition, he is interested in engineering of mammalian cells to establish relevant and standardizable cell model systems and cell factories.Johannes Grillari has graduated in Biotechnology at the University of Natural Resources and Life Sciences Vienna (BOKU), where he completed his PhD in the field of cell aging in 1999. He has founded and has been leading research groups on cellular aging and tissue regeneration since then. He has published more than 200 peer reviewed articles, is co-inventor of 15 patents, a co-founder of 4 companies, and has been invited speaker to more than 150 international conferences and departmental seminars. He has received several awards including the Walter-Doberauer award for aging research.\"I have worked in the field of stem cell science and aging since 2000. ACP-01 is unique and its study results results are very promising,\" said Dr. Grillari. \"I look forward to working with the other members of the SAB in support of the Company's contribution to science and commercialization goals,\" said Dr. Grillari. \"As one of Europe's most well-regarded cell aging scientist, Dr. Grillari is a great addition to our SAB team, as he enables us to bridge to Europe. We are delighted to welcome Dr. Grillari to our SAB, and I very much look forward to his counsel,\" stated Thomas Smeenk, CEO. ABOUT HEMOSTEMIXHemostemix is an autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the C...